

Anti-Hypertension Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Anti-Hypertension Therapeutics - Pipeline Assessment and Market Forecasts to 2018

GlobalData

Date: Oct, 2011

Pages: 112

Price: US\$ 3,500.00

ID: A590AF9C919EN

Anti-Hypertension Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, "Anti-Hypertension Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global anti-hypertension therapeutics market. The report identifies the key trends shaping and driving the global anti-hypertension therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global anti-hypertension therapeutics sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData estimated the global anti-hypertension therapeutics market to be worth \$30.3 billion in 2010, having grown at a CAGR of 4.2% from \$24.6 billion in 2005. The market is forecast to decline at a Compound Annual Growth Rate (CAGR) of 2.3% to be worth \$25.1 billion in 2018. The decline in the anti-hypertension therapeutics market during the forecast period is due to the increasing availability of generic anti-hypertension drugs. The major drugs that are set to lose their patent exclusivity in the forecast period to 2018 are spread across various classes of therapy for the treatment of hypertension, namely angiotensin receptor blockers (ARBs), angiotensin converting enzyme (ACE) inhibitors, calcium channel blockers (CCBs), β -blockers, β -blockers (BB), diuretics and direct rennin inhibitors (DRI).

Note: This is a on-demand report and will be delivered within 3 business days of the purchase (excluding weekends).

Scope

The report provides information on the key drivers and challenges of the anti-hypertension therapeutics market. Its scope includes -

- 1. Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) anti-hypertension therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018.
- 2. Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as endothelium receptor antagonist, vasopeptidase inhibitor, vaccine, glycogen synthase kinase 3 beta (GSK3B) inhibitor (monoclonal antibody), peroxisome proliferator activator receptor (PPAR) agonist, chaperone activator, aldosterone synthase inhibitor, sodium dependent glucose cotransporter 2 inhibitor, natriuretic peptide receptor agonist, opioid-1 (ORL1) agonist, nuclear endopeptidase inhibitor, ouabain antagonist, MAS G protein-coupled receptor (GPCR) agonists and RAAS inhibitors
- 3. Analysis of the current and future competition in the seven key countries anti-hypertension

therapeutics market. Key market players covered are Takeda Pharmaceutical, Aptalis, Novartis AG and Sanofi.

- 4. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- 5. Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the anti-hypertension therapeutics therapeutics market.
- 6. Analysis of key recent licensing and partnership agreements in anti-hypertension therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global anti-hypertension therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global anti-hypertension therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global anti-hypertension therapeutics market landscape? - Identify, understand and capitalize.

Table of Content

1 TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2 ANTI-HYPERTENSION THERAPEUTICS: EXECUTIVE SUMMARY

- 2.1 The Anti-Hypertension Therapeutics Market is Expected to Witness Steep Decline Due to the Impending Patent Expiry of Blockbusters
- 2.2 The Current Competition in the Anti-Hypertension Therapeutics Market is Strong
- 2.3 The Anti-Hypertension Therapeutics Pipeline is Weak, Lacking Novel Therapies in Phase III of Clinical Development
- 2.4 Significant Unmet Need in the Anti-Hypertension Therapeutics Market in Terms of Drugs with Better Safety, Cardiovascular Disease Risk Elimination and Patient Compliance

3 ANTI-HYPERTENSION THERAPEUTICS: INTRODUCTION

- 3.1 Overview
- 3.2 Epidemiology
- 3.3 Etiology
- 3.4 Signs and Symptoms
- 3.5 Diagnosis

- 3.5.1 Medical History
- 3.5.2 Physical Examination
- 3.5.3 Routine Diagnostic Evaluations
- 3.6 Pathophysiology
- 3.7 Treatment and Management Pattern
 - 3.7.1 Angiotensin II Receptor Blockers (ARB)
 - 3.7.2 Angiotensin Converting Enzyme (ACE) Inhibitors
 - 3.7.3 Diuretics
 - 3.7.4 Beta Blockers (BB)
 - 3.7.5 Calcium Channel Blockers (CCBs)
 - 3.7.6 Direct Renin Inhibitors (DRIs)
- 3.8 GlobalData Pipeline Report Guidance

4 ANTI-HYPERTENSION THERAPEUTICS: MARKET CHARACTERIZATION

- 4.1 Overview
- 4.2 Anti-Hypertension Therapeutics Market Size (2005–2010) – Global
- 4.3 Anti-Hypertension Therapeutics Market Forecast (2010–2018) – Global
- 4.4 Anti-Hypertension Therapeutics Market Size (2005–2010) – The US
- 4.5 Anti-Hypertension Therapeutics Market Forecast (2010–2018) – The US
- 4.6 Anti-Hypertension Therapeutics Market Size (2005–2010) – France
- 4.7 Anti-Hypertension Therapeutics Market Forecast (2010–2018) – France
- 4.8 Anti-Hypertension Therapeutics Market Size (2005–2010) – Germany
- 4.9 Anti-Hypertension Therapeutics Market Forecast (2010–2018) – Germany
- 4.10 Anti-Hypertension Therapeutics Market Size (2005–2010) – Italy
- 4.11 Anti-Hypertension Therapeutics Market Forecast (2010–2018) – Italy
- 4.12 Anti-Hypertension Therapeutics Market Size (2005–2010) – Spain
- 4.13 Anti-Hypertension Therapeutics Market Forecast (2010–2018) – Spain
- 4.14 Anti-Hypertension Therapeutics Market Size (2005–2010) – The UK
- 4.15 Anti-Hypertension Therapeutics Market Forecast (2010–2018) – The UK
- 4.16 Anti-Hypertension Therapeutics Market Size (2005–2010) – Japan
- 4.17 Anti-Hypertension Therapeutics Market Forecast (2010–2018) – Japan
- 4.18 Drivers and Barriers for Anti-Hypertension Therapeutics Market
 - 4.18.1 Drivers for the Anti-Hypertension Therapeutics Market
 - 4.18.2 Barriers for the Anti-Hypertension Therapeutics Market
- 4.19 Opportunity and Unmet Need Analysis
- 4.20 Key Takeaway

5 ANTI-HYPERTENSION THERAPEUTICS: COMPETITIVE ASSESSMENT

- 5.1 Overview
- 5.2 Strategic Competitor Assessment
- 5.3 Product Profile for the Major Marketed Products in the Anti-Hypertension Therapeutics
 - 5.3.1 Diovan (valsartan)
 - 5.3.2 Cozaar (losartan)
 - 5.3.3 Vasotec (enalapril)
 - 5.3.4 Lotensin (benazepril)
 - 5.3.5 Thiazide Diuretics
 - 5.3.6 Loop Diuretics
 - 5.3.7 Toprol-XL (metoprolol succinate)
 - 5.3.8 Tenormin (atenolol)
 - 5.3.9 Norvasc (amlodipine)
 - 5.3.10 Tekturna (aliskiren)
- 5.4 Key Takeaway

6 ANTI-HYPERTENSION THERAPEUTICS: PIPELINE ASSESSMENT

- 6.1 Overview
- 6.2 Strategic Pipeline Assessment
- 6.3 Anti-Hypertension Therapeutics Pipeline – Pipeline by Phases of Development
 - 6.3.1 Anti-Hypertension Therapeutics – Phase III and Regulatory Filed Clinical Pipeline
 - 6.3.2 Anti-Hypertension Therapeutics – Phase II Clinical Pipeline
 - 6.3.3 Anti-Hypertension Therapeutics – Phase I Clinical Pipeline
 - 6.3.4 Anti-Hypertension Therapeutics – Pre-Clinical Pipeline
 - 6.3.5 Technology Trends Analytic Framework
- 6.4 Anti-Hypertension Therapeutics Market – Clinical Pipeline by Mechanism of Action
- 6.5 Anti-Hypertension Therapeutics – Drugs Under Clinical Development
- 6.6 Anti-Hypertension Therapeutics – Molecule Profile for Promising Drugs Under Clinical Development
 - 6.6.1 TAK-491
 - 6.6.2 EUR 1000 (Extended release propranolol)
 - 6.6.3 Irbesartan/Amlodipine
 - 6.6.4 S-474474
 - 6.6.5 Telmisartan + Amlodipine + Hydrochlorothiazide
- 6.7 Anti-Hypertension Therapeutics – Other Promising Drugs Under Clinical Development
 - 6.7.1 LCZ696
- 6.8 Key Takeaway

7 ANTI-HYPERTENSION THERAPEUTICS: CLINICAL TRIAL MAPPING

- 7.1 Clinical Trials by Region/Country
- 7.2 Clinical Trials by Phase
- 7.3 Clinical Trials by Trial Status
- 7.4 Clinical Trials Mapping by Sponsors
- 7.5 Clinical Trials Mapping by Prominent Sponsors
- 7.6 Top Companies Participating in Anti-Hypertension Therapeutics Clinical Trials

8 ANTI-HYPERTENSION THERAPEUTICS: STRATEGIC ASSESSMENT

- 8.1 Key Events Affecting the Future Market
- 8.2 Implications for Future Market Competition

9 ANTI-HYPERTENSION THERAPEUTICS: FUTURE PLAYERS

- 9.1 Introduction
- 9.2 Company Profiles
 - 9.2.1 Takeda Pharmaceutical Company Limited
 - 9.2.2 Aptalis
 - 9.2.3 Novartis AG
 - 9.2.4 Sanofi
- 9.3 Other Companies in the Anti-Hypertension Therapeutics Market

10 ANTI-HYPERTENSION THERAPEUTICS: LICENSING AND PARTNERSHIP DEALS

11 ANTI-HYPERTENSION THERAPEUTICS: APPENDIX

- 11.1 Market Definitions
- 11.2 Abbreviations
- 11.3 Methodology
 - 11.3.1 Coverage
 - 11.3.2 Secondary Research

- 11.3.3 Forecasting
- 11.3.4 Primary Research
- 11.3.5 Expert Panel Validation
- 11.4 Contact Us
- 11.5 Disclaimer
- 11.6 Bibliography

LIST OF TABLES

- Table 1: Classification of BP
- Table 2: Recommendations for Follow-up Based on Initial BP Measurements for Adults Without Acute End-Organ Damage
- Table 3: Complications of Various Types of Hypertension
- Table 4: Major Risk Factors for Developing Hypertension
- Table 5: Baseline Blood Tests Recommended by JNC-7
- Table 6: Clinical Implications of Abnormal Laboratory Tests
- Table 7: Risk Stratification of BP to Quantify Prognosis
- Table 8: Major Therapeutic Classes of Anti-Hypertension Drugs
- Table 9: Anti-Hypertension Therapeutics Market, Global, Revenue, (\$bn), 2005–2010
- Table 10: Anti-Hypertension Therapeutics Market, Global, Forecast (\$bn), 2010–2018
- Table 11: Anti-Hypertension Therapeutics Market, The US, Revenue (\$bn), 2005–2010
- Table 12: Anti-Hypertension Therapeutics Market, The US, Forecast (\$bn), 2010–2018
- Table 13: Anti-Hypertension Therapeutics Market, France, Revenue (\$bn), 2005–2010
- Table 14: Anti-Hypertension Therapeutics Market, France, Forecast (\$bn), 2010–2018
- Table 15: Anti-Hypertension Therapeutics Market, Germany, Revenue (\$bn), 2005–2010
- Table 16: Anti-Hypertension Therapeutics Market, Germany, Forecast (\$bn), 2010–2018
- Table 17: Anti-Hypertension Therapeutics Market, Italy, Revenue (\$bn), 2005–2010
- Table 18: Anti-Hypertension Therapeutics Market, Italy, Forecast (\$bn), 2010–2018
- Table 19: Anti-Hypertension Therapeutics Market, Spain, Revenue (\$bn), 2005–2010
- Table 20: Anti-Hypertension Therapeutics Market, Spain, Forecast (\$bn), 2010–2018
- Table 21: Anti-Hypertension Therapeutics Market, The UK, Revenue (\$bn), 2005–2010
- Table 22: Anti-Hypertension Therapeutics Market, The UK, Forecast (\$bn), 2010–2018
- Table 23: Anti-Hypertension Therapeutics Market, Japan, Revenue (\$bn), 2005–2010
- Table 24: Anti-Hypertension Therapeutics Market, Japan, Forecast (\$bn), 2010–2018
- Table 25: Anti-Hypertension Therapeutics – Phase III and Regulatory Filed Pipeline, 2011
- Table 26: Anti-Hypertension Therapeutics – Phase II Clinical Pipeline, 2011
- Table 27: Anti-Hypertension Therapeutics – Phase I Clinical Pipeline, 2011
- Table 28: Anti-Hypertension Therapeutics – Pre-Clinical Pipeline, 2011
- Table 29: Anti-Hypertension Therapeutics – Most Promising Drugs Under Clinical Development, 2010
- Table 30: Anti-Hypertension Therapeutics Market, Clinical Trials by Region/Country, (Number), 2011
- Table 31: Anti-Hypertension Therapeutics Market, Clinical Trials by Phase, 2011
- Table 32: Anti-Hypertension Therapeutics Market, Clinical Trials by Trial Status, 2011
- Table 33: Anti-Hypertension Therapeutics Market, Clinical Trials by Overall Sponsors, 2011
- Table 34: Anti-Hypertension Therapeutics Market, Clinical Trials by Prominent Sponsors, 2011
- Table 35: Anti-Hypertension Therapeutics Market, Companies Participating in Clinical Trials, 2011
- Table 36: Takeda – Anti-Hypertension Pipeline Products, 2011
- Table 37: Aptalis – Cardiovascular Pipeline Products, 2011
- Table 38: Novartis AG – Anti-Hypertension Pipeline Products, 2011
- Table 39: Sanofi – Anti-Hypertension Pipeline Products, 2011
- Table 40: Other Companies in the Anti-Hypertension Therapeutics Market
- Table 41: Anti-Hypertension Therapeutics Market, Global, Deals, 2011

LIST OF FIGURES

- Figure 1: BPH Therapeutics Market, Global, Revenues and Market Forecast (\$bn), 2005–2018

- Figure 2: Opportunity and Unmet Need in the BPH Therapeutics Market, 2011
- Figure 3: Benign Prostatic Hyperplasia (BPH)
- Figure 4: Benign Prostatic Hyperplasia Therapeutics Market, Global, Revenue (\$bn), 2005–2010
- Figure 5: Benign Prostatic Hyperplasia Therapeutics, Market Share (\$m), 2010
- Figure 6: Benign Prostatic Hyperplasia Therapeutics Market, Global, Forecast (\$bn), 2010–2018
- Figure 7: Benign Prostatic Hyperplasia Therapeutics, Market Share (\$m), 2018
- Figure 8: Benign Prostatic Hyperplasia Therapeutics Market, The US, Revenue (\$bn), 2005–2010
- Figure 9: Benign Prostatic Hyperplasia Therapeutics Market, The US, Forecast (\$bn), 2010–2018
- Figure 10: Benign Prostatic Hyperplasia Therapeutics Market, The UK, Revenue (\$m), 2005–2010
- Figure 11: Benign Prostatic Hyperplasia Therapeutics Market, The UK, Forecast (\$m), 2010–2018
- Figure 12: Benign Prostatic Hyperplasia Therapeutics Market, France, Revenue (\$m), 2005–2010
- Figure 13: Benign Prostatic Hyperplasia Therapeutics Market, France, Forecast (\$m), 2010–2018
- Figure 14: Benign Prostatic Hyperplasia Therapeutics Market, Germany, Revenue (\$m), 2005–2010
- Figure 15: Benign Prostatic Hyperplasia Therapeutics Market, Germany, Forecast (\$m), 2010–2018
- Figure 16: Benign Prostatic Hyperplasia Therapeutics Market, Italy, Revenue (\$m), 2005–2010
- Figure 17: Benign Prostatic Hyperplasia Therapeutics Market, Italy, Forecast (\$m), 2010–2018
- Figure 18: Benign Prostatic Hyperplasia Therapeutics Market, Spain, Revenue (\$m), 2005–2010
- Figure 19: Benign Prostatic Hyperplasia Therapeutics Market, Spain, Forecast (\$m), 2010–2018
- Figure 20: Benign Prostatic Hyperplasia Therapeutics Market, Japan, Revenue (\$m), 2005–2010
- Figure 21: Benign Prostatic Hyperplasia Therapeutics Market, Japan, Forecast (\$m), 2010–2018
- Figure 22: Opportunity and Unmet Need in the BPH Therapeutics Market, 2011
- Figure 23: Strategic Competitor Assessment of the Marketed Products for BPH Therapeutics, 2011
- Figure 24: Benign Prostatic Hyperplasia Therapeutics Pipeline by Phase of Clinical Development, 2011
- Figure 25: Technology Trends Analytic Framework of the BPH Therapeutics Pipeline, 2011
- Figure 26: Technology Trends Analytic Framework of the BPH Therapeutics Pipeline – Description, 2010
- Figure 27: Benign Prostatic Hyperplasia Therapeutics – Pipeline by Mechanism of Action, 2011
- Figure 28: Benign Prostatic Hyperplasia Therapeutics – Clinical Trials by Country, 2011
- Figure 29: Benign Prostatic Hyperplasia Therapeutics – Clinical Trials by Phase, 2011
- Figure 30: Benign Prostatic Hyperplasia Therapeutics – Clinical Trials by Status, 2011
- Figure 31: Benign Prostatic Hyperplasia Therapeutics – Clinical Trials by Overall Sponsors, 2011
- Figure 32: Benign Prostatic Hyperplasia Therapeutics – Clinical Trials by Prominent Sponsors, 2011
- Figure 33: Benign Prostatic Hyperplasia – Clinical Trials by Top Sponsors, 2011
- Figure 34: Benign Prostatic Hyperplasia Therapeutics Market, Drivers and Barriers, 2011
- Figure 35: Implications for Future Market Competition in Benign Prostatic Hyperplasia Therapeutic Market, 2011
- Figure 36: Benign Prostatic Hyperplasia Therapeutics – Pipeline by Company, 2011
- Figure 37: GlobalData Market Forecasting Model

COMPANIES MENTIONED

Takeda Pharmaceutical Company Limited
Aptalis
Novartis AG
Sanofi

I would like to order:

Product name: Anti-Hypertension Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Product link: <http://marketpublishers.com/r/A590AF9C919EN.html>
Product ID: A590AF9C919EN
Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service: office@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button on product page <http://marketpublishers.com/r/A590AF9C919EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
E-mail:
Company:
Address:
City:
Zip/Post Code:
Country:
Tel:
Fax:
Your message:

* All fields are required

Customer Signature _____

Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at http://marketpublishers.com/docs/terms_conditions.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to **+44 20 7900 3970**

